Literature DB >> 9891441

Modification of membrane fluidity and depolarization by some anthracyclines in different cell lines.

C Pacilio1, S Florio, U Pagnini, A Crispino, P P Claudio, G Pacilio, G Pagnini.   

Abstract

One of the major problems in cancer treatment is the progressive desensitization of cancer cells to chemotherapeutic drugs. Several hypotheses have been advanced to explain this property of cancer cells. In recent years different calcium channel blockers and other chemosensitizing agents like synthetic progestins have been used to revert drug resistance. In our experiments we evaluated the effects of Doxorubicin and Idarubicin on membrane fluidity and depolarization using normal lymphocytes, chronic lymphatic leukemia lymphocytes, normal breast and hormone dependent breast cancer cells and cardiomyocytes. The drugs were used alone or in combination with Verapamil and Medroxyprogesterone acetate. We showed that MPA enhances DOXO and IDA biochemical effects, acting not only on the membrane lipid bilayer, but also on ion channels. VERA instead does not seem to act through the same mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891441

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Effect of "All - trans" retinoic acid in canine osteosarcoma chemotherapy.

Authors:  R Ciarcia; C Pagnini; F Fiorito; A Pellicane; S Montagnaro; R Russo; S Florio
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

Review 2.  Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics.

Authors:  Eric Krueger; Angela C Brown
Journal:  Mol Oral Microbiol       Date:  2020-03-10       Impact factor: 3.563

3.  Inhibition of Bacterial Toxin Activity by the Nuclear Stain, DRAQ5™.

Authors:  Joshua N Webb; Evan Koufos; Angela C Brown
Journal:  J Membr Biol       Date:  2016-04-02       Impact factor: 1.843

4.  Cholesterol dependent uptake and interaction of doxorubicin in mcf-7 breast cancer cells.

Authors:  Petra Weber; Michael Wagner; Herbert Schneckenburger
Journal:  Int J Mol Sci       Date:  2013-04-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.